Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

Cancer Cell 2015 Dec;28(6):773-784

Department of Neurosurgery, Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address:

Heterozygous mutation of IDH1 in cancers modifies IDH1 enzymatic activity, reprogramming metabolite flux and markedly elevating 2-hydroxyglutarate (2-HG). Here, we found that 2-HG depletion did not inhibit growth of several IDH1 mutant solid cancer types. To identify other metabolic therapeutic targets, we systematically profiled metabolites in endogenous IDH1 mutant cancer cells after mutant IDH1 inhibition and discovered a profound vulnerability to depletion of the coenzyme NAD+. Mutant IDH1 lowered NAD+ levels by downregulating the NAD+ salvage pathway enzyme nicotinate phosphoribosyltransferase (Naprt1), sensitizing to NAD+ depletion via concomitant nicotinamide phosphoribosyltransferase (NAMPT) inhibition. NAD+ depletion activated the intracellular energy sensor AMPK, triggered autophagy, and resulted in cytotoxicity. Thus, we identify NAD+ depletion as a metabolic susceptibility of IDH1 mutant cancers.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2015.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684594PMC
December 2015
87 Reads
46 Citations
23.523 Impact Factor

Publication Analysis

Top Keywords

nad+ depletion
16
idh1 mutant
16
mutant cancers
8
idh1
8
mutant idh1
8
nad+
7
depletion
6
mutant
6
targets systematically
4
therapeutic targets
4
activated intracellular
4
downregulating nad+
4
profiled metabolites
4
intracellular energy
4
systematically profiled
4
levels downregulating
4
depletion activated
4
nad+ salvage
4
cancer types
4
energy sensor
4

Similar Publications